rabeprazole / Generic mfg. |
ChiCTR-TRC-12002607: The effect of different proto pump inhibitor in dual anti - platelet therapy with aspirin and clopidogrel in patients with acute coronary syndrome |
|
|
| Completed | 4 | 400 | | omeprazole ;lansoprazole ;Rabeprazole ;Rabeprazole | Affiliated Jiangyin Hospital, College of Medicine, Southeast University; Affiliated Jiangyin Hospital, College of Medicine, Southeast University, Supported by the Research Project and investigator | coronary heart disease | | | | |
ChiCTR1800014832: Different antibiotic combinations, different doses of rabeprazole quadruple therapy for helicobacter pylori associated with duodenal ulcer: a multicentric, randomized, parallel control clinical study. |
|
|
| Completed | 4 | 440 | | rabeprazole 10 mg and bismuth 220 mg b.i.d., plus amoxicillin 1000 mg and clarithromycin 500 mg b.i.d. ;rabeprazole 10 mg and bismuth 220 mg b.i.d., plus amoxicillin 1000 mg and tetracycline 750 mg b.i.d. ;rabeprazole 20 mg and bismuth 220 mg b.i.d., plus amoxicillin 1000 mg and clarithromycin 500 mg b.i.d. ;rabeprazole 20 mg and bismuth 220 mg b.i.d., plus amoxicillin 1000 mg and tetracycline 750 mg b.i.d | The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, the Chinese Study Group on Helicobacter pylori, Chinese Society of Gastroenterology | helicopter pylori and duodenal ulcer | | | | |
2009-011543-40: Assessment of platelet inhibitory response to clopidogrel when coadministered with a proton pump inhibitor |
|
|
| Ongoing | 4 | 72 | Europe | Omeprazole, Pariet (Rabeprazole), Zantac, Omeprazole (Losec), Pariet, Zantac (Ranitidine), Omeprazole (Losec), Pariet, Zantac (Ranitidine) | Papworth Hospital | To investigate in patients undergoing elective coronary stenting, the interaction between omeprazole, rabeprazole and ranitidine on clopodogrel inhibition of platelet activity in wild type (wt/wt) CYP2C19 “extensive metabolisers”, using VerifyNow-P2Y12 assay clopidogrel assay. We will also indirectly assess the effect of clopidogrel on acid suppression by measuring gastrin hormone levels that are directly related to stomach pH. | | | | |
ChiCTR-IPR-16010286: Evaluation of quadruple therapy regimens of Helicobacter pylori eradication based on different proton pump inhibitors |
|
|
| Recruiting | 4 | 245 | | SOMAC ;Pantoloc ;Takepron ;Nexium ;Pariet ;SOMAC+probiotic ;none | Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Z hejiang University; Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Z hejiang University, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University | Helicobacter pylori infection | | | | |
ChiCTR1800020352: Open, multicenter, single-arm clinical study of large dose rabeprazole sodium in the treatment of peptic ulcer bleeding |
|
|
| Not yet recruiting | 4 | 45 | | (1) 40mg rapeprazole sodium for injection was added into 0.9% sodium chloride injection 100ml, and the infusion was completed within 30min; (2) then the micropump was continuously pumped at a speed of 4mg/h for 72h; (3) the standard dose of rabeprazole sodium for injection: 20mg, bid, intravenous infusion w | Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Shenzhen liancheng pharmaceutical co., LTD, self-raised funds | peptic ulcer bleeding | | | | |
ChiCTR2100053126: Analysis of Factors Associated with Mood Disorders and the Efficacy of Targeted Treatment of Functional Dyspepsia: a Randomized, Positive Drug Controlled, Prospective Study |
|
|
| Completed | 4 | 362 | | flupentixol and melitracen + nizatidine ;flupentixol and melitracen + rabeprazole ;flupentixol and melitracen ;nizatidine ;rabeprazole | The Third Xiangya Hospital, Central South University; Digestive System Department, The Third Xiangya Hospital, Central South University, the New Xiangya Talent Project of the Third xiangya hosipital of Central South University (20180304); Hunan Provincial Natural Science Foundation of China(2020JJ4853), etc. | functional dyspepsia | | | | |
TRIVON, NCT03908619: A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis |
|
|
| Recruiting | 4 | 252 | RoW | Omeprazole 20mg, Losec, Esomeprazole 20mg, Nexium, Rabeprazole Sodium 20mg, Pariet, Vonoprazan, Vocinti | Changi General Hospital | Helicobacter Pylori Infection | 03/21 | 03/21 | | |
ChiCTR2000040051: Rabeprazole with amoxicillin or furazolidone dual therapy for helicobacter pylori infection: a single center, prospective, randomized, open-label controlled trial |
|
|
| Recruiting | 4 | 360 | | bismuth quadruple therapy ;Amoxicillin dual therapy ;Furazolidone dual therapy | Henan Provincial People's Hospital; Henan Provincial People's Hospital, Henan Provincial Medical Science and Technology Research Project | helicobacter pylori infection | | | | |
ChiCTR2000041211: Efficacy and safety of Sucralfate Suspensoid Gel in the treatment of Helicobacter pylori associated gastritis after eradication with standard quadruple therapy: a multicenter randomized controlled trial |
|
|
| Recruiting | 4 | 300 | | Rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg and colloidal bismuth pectin 200 mg, all twice daily for 14 days ;After the use of rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg and colloidal bismuth pectin 200 mg, all twice daily for 14 days, take Sucralfate Suspensoid Gel twice a day for 14 days. | Shandong Provincial Hospital; Shandong Provincial Hospital, Kunming Jida Pharmaceutical | Helicobacter pylori associated gastritis | | | | |
ChiCTR2100045530: A preliminary study on the efficacy and safety of proton pump inhibitors combined with agomelatine in the treatment of gastroesophageal reflux disease |
|
|
| Recruiting | 4 | 80 | | On the basis of proton pump inhibitor (rabeprazole 20mg, orally, 1 day), agomelatine 25mg/d was added, orally before bedtime ;On the basis of proton pump inhibitor (rabeprazole 20mg, orally, 1/ day) treatment, soothing agents were added, orally before bedtime | Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Jiangsu Hansoh Pharmaceutical Group Co. Ltd | Gastroesophageal reflux disease (GERD) | | | | |
NCT04667299: Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment |
|
|
| Recruiting | 4 | 270 | RoW | Rabeprazole, Bismuth potassium citrate, Metronidazole, Amoxicillin | Shanghai Zhongshan Hospital | Helicobacter Pylori Infection | 11/21 | 12/21 | | |
ChiCTR2100052576: Analysis of efficacy of vonoprazan and rabeprazole in Helicobacter pylori eradication therapy |
|
|
| Recruiting | 4 | 240 | | vonoprazan 20mg,2 times a day for 7days ;vonoprazan 20mg,2 times a day for 14 days ;rabeprazole 10mg,2 times a day for 14 days | Department of Gastroenterology, Jinshan Hospital of the First Affiliated Hospital of Chongqing Medical University; Jinshan Hospital of the First Affiliated Hospital of Chongqing Medical University, Postgraduate funding | Helicobacter pylori infection | | | | |
| Recruiting | 4 | 732 | RoW | Rabeprazole, Bismuth potassium citrate, Metronidazole, Amoxicillin | Shanghai Zhongshan Hospital | Helicobacter Pylori Infection | 12/22 | 12/22 | | |
NCT05018923: Tetracycline Versus Doxycycline for HP Rescue Therapy |
|
|
| Recruiting | 4 | 242 | RoW | Rabeprazole, Bismuth potassium citrate, Metronidazole, Doxycycline, Tetracycline | Shanghai Zhongshan Hospital | Helicobacter Pylori Infection | 12/22 | 12/22 | | |
NCT05023577: Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients |
|
|
| Recruiting | 4 | 504 | RoW | Rabeprazole, Bismuth potassium citrate, Metronidazole, Clarithromycin, Levofloxacin | Shanghai Zhongshan Hospital | Helicobacter Pylori Infection | 12/22 | 12/22 | | |
NCT05419674: Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection |
|
|
| Recruiting | 4 | 393 | RoW | Vonoprazan, Rabeprazole, Amoxicillin, Clarithromycin, Colloidal bismuth pectin | Second Affiliated Hospital, School of Medicine, Zhejiang University | Helicobacter Pylori Infection | 08/23 | 08/23 | | |
ChiCTR2300068440: Bismuth-containing Quadruple Therapy with low-dose Tetracycline for Helicobacter pylori infection eradication: A multi-center randomized controlled trial |
|
|
| Recruiting | 4 | 746 | | Tetracycline 500 mg bid+amoxicillin 1000 mg bid+Rabeprazole 10mg bid+Bismuth potassium citrate 600mg/Colloidal bismuth pectin 200mg bid ;Tetracycline 500 mg tid+amoxicillin 1000 mg bid+Rabeprazole 10mg bid+Bismuth potassium citrate 600mg/Colloidal bismuth pectin 200mg bid | Sir Run Run Shaw Hospital; Sir Run Run Shaw Hospital, Sir Run Run Shaw Hospital | Heilicobacter pylori infection | | | | |
NCT06168214: Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication |
|
|
| Recruiting | 4 | 1404 | RoW | Rabeprazloe+bismuth+amoxicillin+clarithromycin, Vonoprazan+amoxicillin+clarithromycin 14 days, Vonoprazan+amoxicillin+clarithromycin 7 days, Vonoprazan+tetracycline+furazolidone 14 days, Vonoprazan+tetracycline+furazolidone 7 days, Vonoprazan+amoxicillin+furazolidone 7 days, Vonoprazan+amoxicillin+tetracycline 14 days, Vonoprazan+amoxicillin 7 days, Vonoprazan+amoxicillin 14 days | Xijing Hospital of Digestive Diseases | the Eradication Rates of Helicobacter Pylori | 11/24 | 12/24 | | |
ChiCTR2200066296: Single center, randomized, controlled, open, non inferiority clinical trial of the quadruple therapy of Qingwei Zhitong pellets instead of bismuth in the treatment of helicobacter pylori |
|
|
| Recruiting | 4 | 334 | | 10mg Bid for breakfast and 0.5-1h before dinner, 3.2 g Tid for rabeprazole, 0.5-1h before lunch and 0.5-1h before dinner, 1g Bid for Amoxicillin, take Clarithromycin 500mg Bid at breakfast and immediately after dinner ;Rabeprazole 10 mg Bid at breakfast and 0.5-1 h before dinner, bismuth complex 2.6 g tid at breakfast, lunch and 0.5-1 h before dinner, Amoxicillin 1g Bid, take Clarithromycin 500mg Bid at breakfast and immediately after dinner | Civil Aviation General Hospital; Civil Aviation General Hospital, Jilin Huakang Pharmaceutical Co., Ltd | Helicobacter pylori | | | | |
ChiCTR2200062264: Efficacy and safety of Vonoprazan combined with high dose amoxicillin in the treatment of Helicobacter pylori infection |
|
|
| Not yet recruiting | 4 | 500 | | The treatment lasted for 10 days, including vonoprazan 20mg twice a day, amoxicillin 1g three times a day ;The treatment lasted for 10 days, including vonoprazan 20mg twice a day, amoxicillin 1g three times a day, furazolidone 100mg twice a day ;The treatment lasted for 14 days, including vonoprazan 20mg twice a day, amoxicillin 1g three times a day ;Amoxicillin 1g twice a day, clarithromycin sustained-release tablet 0.5g twice a day, rabeprazole sodium enteric-soluble capsule 20mg twice a day, colloidal bismuth 0.3g twice a day. Patients were treated for 14 days | Xuzhou First People's Hospital; Xuzhou First People's Hospital, None | Helicobacter pylori infection | | | | |
NCT05718609: Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection |
|
|
| Recruiting | 4 | 855 | RoW | Rabeprazole, Colloidal Bismuth Pectin Granules, Amoxicillin, Furazolidone, Clarithromycin | Second Affiliated Hospital, School of Medicine, Zhejiang University | Helicobacter Pylori Infection | 03/24 | 06/24 | | |
ChiCTR2300070080: Clinical observation of Qiruiweishu capsule combined with conventional western medicine in the treatment of chronic gastritis with erosion |
|
|
| Not yet recruiting | 4 | 500 | | On the basis of basic treatment, the patients were given rabeprazole sodium enteric-coated tablets (Jichuan Pharmaceutical Group Co., Ltd., GYZZ H20040916, specification: 10mg/tablet), 10 mg/time, twice a day, for 28 days; If accompanied by Helicobacter pylori infection, the patient should be treated with quadruple antibiotic (Rabeprazole 10mg bid, amoxicillin potassium clavulanic acid 5 pills bid, clarithromycin 0.5 bid, bismuth potassium citrate 220 mg bid) for 14 days. Stop taking medication for 14 days and undergo gastroscopy and Helicobacter pylori examination. ;On the basis of basic treatment, the patient was given Qiruiweishu capsule, 4 capsules at a time, twice a day; Rabeprazole sodium enteric-coated tablets (Jichuan Pharmaceutical Group Co., Ltd., GYZZ H20040916, specification: 10mg/tablet), 10 mg/time, twice a day. Take it continuously for 28 days. In the same way, the patients with Helicobacter pylori infection were treated with quadruple antimicrobial therapy (rabeprazole 10 mg bid, amoxicillin potassium clavulanic acid 5 pills bid, clarithromycin 0.5 bid, bismuth potassium citrate 220 mg bid) for 14 days in the first week. Stop taking medication for 14 days and undergo gastroscopy and Helicobacter pylori examination. | Jiangsu Second Hospital of Traditional Chinese Medicine; Jiangsu Second Hospital of Traditional Chinese Medicine, Jianmin Pharmaceutical Group Co., Ltd. | chronic gastritis | | | | |
ChiCTR2300069313: Effect and mechanism of combined proton pump inhibitors and rifaximin treatment in functional dyspepsia patients |
|
|
| Not yet recruiting | 4 | 96 | | Rifaximin 1200 mg given at 400 mg three times per day for 2 weeks; Rabeprazole 10mg once daily for 4 weeks ;Rabeprazole 10mg once daily for 4 weeks | Gastroenterology Department of Peking University Third Hospital; Peking University Third Hospital, National Key Research and Development Program of China (No. 2019YFA0905600) | Functional Dyspepsia | | | | |
NCT03897244: Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication |
|
|
| Recruiting | 4 | 702 | RoW | High-dose dual therapy (rabeprazole, amoxicillin), Proton pump inhibitor, Rabeprazole, Pariet®, Antibiotics, Amoxicillin ,Amoxicillin®, Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate), Colloidal Bismuth, Tripotassium dicitrate bismuthate, KCB®, Amoxicillin-Metronidazole Bismuth quadruple therapy, Antibiotics, Amoxicillin, Amoxicillin®, Antibiotics, Metronidazole, Flagyl® | National Taiwan University Hospital, Ministry of Science and Technology, Taiwan | Helicobacter Pylori Infection | 09/24 | 12/24 | | |
ChiCTR2300076151: A study on first-line therapy for Helicobacter pylori infection in patients with penicillin allergy using a bismuth-containing quadruple therapy with rabeprazole, cefuroxime, and doxycycline |
|
|
| Recruiting | 4 | 110 | | Bismuth-Containing Quadruple Therapy | The First Affiliated Hospital, Ningbo University; The First Affiliated Hospital, Ningbo University, Investigator Initiated Trial Foundation of the First Affiliated Hospital, Ningbo University | Helicobacter pylori infection | | | | |
ChiCTR2300077074: Evaluation of the efficacy of berberine combined with Vonoprazan and amoxicillin for eradication of Helicobacter pylori |
|
|
| Not yet recruiting | 4 | 300 | | Berberine hydrochloride tablets 200mg + Vonoprazan fumarate tablets 20mg + amoxicillin capsule 1g, berberine hydrochloride tablets 3 times a day and all the rest of the medicines were given twice a day for 14 days.; Berberine hydrochloride tablets 300mg + Vonoprazan fumarate tablets 20mg + amoxicillin capsule 1g, berberine hydrochloride tablets 3 times a day, and all the rest of the medicines were given twice a day for 14 days.; Colloidal bismuth pectin capsules 200mg + Rabeprazole sodium enteric-coated tablets 20mg + amoxicillin capsules 1g + clarithromycin tablets 0.5g, all medications were given twice a day for 14 days. | Qianxinan People's Hospital; Qianxinan People's Hospital, self-funded | Helicobacter pylori infection | | | | |
NCT05879029: Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD |
|
|
| Recruiting | 4 | 72 | RoW | Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets., Jinsang Liyan Capsule placebo; Rabeprazole enteric-coated tablets. | Tongji Hospital, Xi'an Beilin Pharmaceutical Co. Ltd | Laryngopharyngeal Reflux | 12/24 | 12/24 | | |
ChiCTR2300077528: A single-center randomized controlled study of Vonoprazan based dual therapy and Rabeprazole based dual therapy for Helicobacter pylori infection |
|
|
| Not yet recruiting | 4 | 364 | | Rabeprazole+Amoxicillin; Vonoprazan + Amoxicillin | Nanjing First Hospital; Nanjing First Hospital, Self-raised | Helicobacter | | | | |
NCT05191888: 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy |
|
|
| Recruiting | 4 | 906 | RoW | Vonoprazan and Amoxicillin, Vonoprazan, Amoxicillin and Clarithromycin, Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole | Kaohsiung Medical University | Helicobacter Pylori Eradication | 12/24 | 12/24 | | |
ChiCTR2300073347: Randomized controlled clinical study of the effects of Wei Chang Hao combined with quadruple therapy on helicobacter pylori eradication rate and intestinal flora |
|
|
| Not yet recruiting | 4 | 130 | | Given Rabeprazole sodium enteric-coated tablets (10 mg/time, twice/day), bismuth potassium citrate capsules (300 mg/time, twice/day), amoxicillin (1,000 mg/time, twice/day) + furazolidone tablets (100mg/time, twice/day) + Wei Chang Hao (2,000 mg/time, three times/day), take it for 14 days. After antibiotic bunching, Wei Chang Hao was continued to be taken (2,000 mg/time, 3 times/day) for 4 weeks. Note: Antibiotics should be taken at a two-hour interval. ;Rabeprazole sodium enteric-coated tablets (10 mg/time, twice a day), bismuth potassium citrate capsules (300 mg/time, twice a day), amoxicillin (1,000 mg/time, twice a day) and furazolidone tablets (100 mg/time, twice a day) were given for 14 days. ;N/A | The First Hospital of Nanchang; The First Hospital of Nanchang, The First Hospital of Nanchang | Helicobacter pylori infection | | | | |
ChiCTR2300070994: A randomized controlled clinical trial on eradication of Helicobacter pylori infection in children |
|
|
| Not yet recruiting | 4 | 174 | | Rabeprazole + amoxicillin + clarithromycin + colloidal bismuth citrate for 14 days ;Rabeprazole + amoxicillin + clarithromycin for 14 days | Guangzhou Women and Children's Medical Center; Guangzhou Women and Children's Medical Center, NO | Helicobacter pylori infection in children | | | | |
ChiCTR2300075479: A randomized, open clinical study to evaluate the efficacy and safety of vonoprazan combined with amoxicillin in the eradication of Helicobacter pylori |
|
|
| Not yet recruiting | 4 | 219 | | Amoxicillin 1g/ twice/day + vonoprazan 20mg/ twice/day (14 days); Amoxicillin 750mg/ time 4 times/day + vonoprazan 20mg/ time 2 times/day (14 days); Amoxicillin 750mg/ time 4 times/day + Rabeprazole 20mg/ time 2 times/day (14 days) | Guangzhou First People’s Hospital; Guangzhou First People’s Hospital, self-financing | Helicobacter pylori | | | | |
NCT05332444: Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection |
|
|
| Recruiting | 4 | 450 | RoW | susceptibility-guided tailored therapy (Group A), Proton pump inhibitor: Rabeprazole, Pariet®, Antibiotics: Amoxicillin, Amoxicillin®; Clarithromycin, Klaricid®; Levofloxacin, Cravit®; Metronidazole, Metrozole®; Tetracyclline, tetracycline®, Colloidal Bismuth: Tripotassium dicitrate bismuthate, KCB®, guidelines-recommended empiric therapy (Group B), Antibiotics: Metronidazole, Metrozole®; Tetracyclline, tetracycline® | National Taiwan University Hospital | Helicobacter Pylori Infection | 09/25 | 12/25 | | |
ChiCTR2400089417: Efficacy study of tegoprazan dual therapy and bismuth containing quadruple therapy for eradication of Helicobacter pylori |
|
|
| Not yet recruiting | 4 | 224 | | Tegoprazan 50mg twice a day and amoxicillin 1.0g three times a day for 10 days; Rabeprazole 20mg twice a day, amoxicillin 1.0g twice a day, Furazolidone 0.1g twice a day, colloidal bismuth pectin 200mg twice a day for 10 days | Chengdu Xinhua Hospital; Chengdu Xinhua Hospital, In-hospital research projects | Helicobacter pylori infection | | | | |
NCT05624229: Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding |
|
|
| Not yet recruiting | 4 | 672 | NA | Proton Pump Inhibitors, Drug: Omeprazole, Drug: Esomeprazole, Drug: Rabeprazole, Drug: Pantoprazole, Drug: Ilaprazole, Drug: Lansoprazole, No Proton Pump Inhibitors | West China Hospital | Upper Gastrointestinal Hemorrhage | 12/25 | 12/28 | | |
ChiCTR2400082227: A national multicenter open randomized parallel controlled clinical study on the first treatment of Helicobacter pylori positive chronic gastritis patients with Compound Eosinophil-Lactobacillus quadruple therapy |
|
|
| Not yet recruiting | 4 | 600 | | Rabeprazole enteric-coated capsule + Amoxicillin capsule + Tetracycline tablet + Compound Eosinophil-Lactobacillus Tablets capsules were taken for 14 days; Rabeprazole enteric-coated capsule + Amoxicillin capsule +Tetracycline tablet + Bismuth potassium citrate capsules + Compound Eosinophil-Lactobacillus Tablets capsules were taken for 10 days, while taking Compound Eosinophil-Lactobacillus Tablets until the 21d; Rabeprazole enteric-coated capsule + Amoxicillin capsule +Tetracycline tablet + Bismuth potassium citrate capsules were taken for 14 days | Peking University First Hospital; Peking University First Hospital, China Health Promotion Foundation | Helicobacter pylori positive chronic gastritis | | | | |
| Recruiting | 4 | 4447 | RoW | Rabeprazole, Bismuth potassium citrate, Metronidazole, Clarithromycin, Levofloxacin, Amoxicillin, Doxycycline, Tetracycline | Shanghai Zhongshan Hospital | Helicobacter Pylori Infection | 06/26 | 06/26 | | |
PROTECT-HBR, NCT04416581: Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy |
|
|
| Recruiting | 4 | 3100 | RoW | PPI, P-CAB 50 | Duk-Woo Park, MD | Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction | 09/26 | 12/27 | | |
ChiCTR2400079666: Protective effect of tipredone on digestive tract mucosa in patients with myocardial infarction |
|
|
| Not yet recruiting | 4 | 160 | | Oral rabeprazole + ticagrelor + aspirin; Teprenone + ticagrelor + aspirin taken orally | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Self-selected project (self-funded) | Following percutaneous coronary intervention (PCI), patients are required to undergo dual antiplatelet therapy (DAPT) comprising a P2Y12 receptor antagonist (Clopidogrel or Ticagrelor) and aspirin in order to mitigate the risk of stent thrombosis. However, DAPT may elevate the likelihood of gastrointestinal bleeding. | | | | |
| Not yet recruiting | 4 | 484 | | Rabeprazole 20 mg twice daily (Bid) + Amoxicillin 1 g Bid + Clarithromycin 500 mg Bid + Potassium Citrate Bismuth 220 mg Bid + Brachyspira Yeast 0.25; Control Group: Rabeprazole 20 mg Bid + Amoxicillin 1 g Bid + Clarithromycin 500 mg Bid + Potassium Citrate Bismuth 220 mg Bid. | The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University, Researcher-initiated Clinical Research Fund Project of the First Affiliated Hospital of Xiamen University | Helicobacter pylori | | | | |
NCT02407119: Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD |
|
|
| Active, not recruiting | 3 | 470 | RoW | 7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin, 7 day Proton pump inhibitor (PPI)-based standard triple therapy, Placebo, Omeprazole or Rabeprazole, Clarithromycin, Placebo | National Cancer Center, Korea | Helicobacter Pylori Infection, Early Gastric Cancer, Endoscopic Resection | 06/16 | 06/30 | | |
NCT03779074: Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies |
|
|
| Completed | 3 | 918 | RoW | 10d bismuth quadruple therapy, rabeprazole 20 mg bid, tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, metronidazole 250 mg qid, 14d hybrid therapy, amoxicillin 1 g bid, clarithromycin 500 mg bid, metronidazole 500 mg bid, 14D high-dose dual therapy, rabeprazole 20 mg qid, amoxicillin 750 mg qid | Kaohsiung Veterans General Hospital. | Helicobacter Pylori Infection | 12/21 | 12/21 | | |
NCT05857163: Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. Pylori Infection |
|
|
| Completed | 3 | 700 | RoW | Rifasutenizol capsules, TNP-2198 capsules, Rabeprazole sodium enteric-coated tablets, Amoxicillin Capsules, Clarithromycin placebo tablets, Bismuth potassium citrate placebo capsules, Clarithromycin tablets, Bismuth potassium citrate capsules, Rifasutenizol placebo capsules | TenNor Therapeutics (Suzhou) Limited | H.Pylori Infection | 03/24 | 03/24 | | |
ChiCTR2300070540: A multicenter, randomized, double-blind, bismuth quadruple positive control phase III clinical trial to evaluate the efficacy and safety of TNP-2198 combined with rabeprazol sodium and amoxicillin in the primary treatment of participants with positive helicobacter pylori infection |
|
|
| Not yet recruiting | 3 | 700 | | TNP-2198 capsules, rabeprazole sodium enteric-coated tablets, amoxicillin capsules ;Amoxicillin capsules, clarithromycin tablets, rabeprazole sodium enteric-coated tablets, Bismuth potassium citrate capsules | Department of Gastroenterology, Peking Universsity Third Hospital; Department of Gastroenterology, Peking University Third Hospital, self-funded | helicobacter pylori infection | | | | |
2013-001096-20: Salvage chemotherapy with daily, low, continuously administered dose of capecitabine and proton-pump inhibitors in advanced gastro-intestinaltumours Terapia di salvataggio con basse dosi di Capecitabina, giornaliera, continuativa, associata ad inibitori di pompa protonica nei tumorigastrointestinali avanzati |
|
|
| Ongoing | 2 | 66 | Europe | Pariet, Xeloda, Capsule, hard, Pariet, Xeloda | Department of Molecular and Clinical Medicine; "Sapienza" University of Rome, Department of Molecular and Clinical Medicine; "Sapienza" University of Rome | Patients with gastrointestinal malignancies ineligible for conventional chemotherapy Pazienti con neoplasie gastrointestinali non eleggibili per un trattamento chemioterapico convenzionale, Patients with advanced tumors of the gastrointestinal tract Pazienti con tumori del tratto gastroenterico avanzati, Diseases [C] - Cancer [C04] | | | | |
NCT06076694: Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants |
|
|
| Completed | 2 | 80 | RoW | TNP-2198, Rifasutenizol, Rabeprazole Sodium, Amoxicillin | TenNor Therapeutics (Suzhou) Limited | Helicobacter Pylori Infection | 09/22 | 09/22 | | |
NCT05604261: A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis |
|
|
| Not yet recruiting | 2 | 156 | RoW | Anaprazole sodium 40 mg, Anaprazole sodium 60 mg, Rabeprazole sodium 20 mg | Xuanzhu Biopharmaceutical Co., Ltd. | Reflux Esophagitis, Gastroesophageal Reflux, Esophagitis, Esophageal Motility Disorders, Deglutition Disorders, Esophageal Diseases, Gastrointestinal Diseases | 07/23 | 03/24 | | |
NCT06076681: A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules |
|
|
| Completed | 1/2 | 40 | RoW | TNP-2198, Rifasutenizol, Rabeprazole Sodium, Amoxicillin | TenNor Therapeutics (Suzhou) Limited | Helicobacter Pylori Infection | 01/22 | 01/22 | | |
NCT05407675: A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 101 | Europe, Canada, US | BMS-986408, Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Platinum-doublet chemotherapy, PDCT, carbplatin, paclitaxel, pemetrexed, cisplatin, Rabeprazole | Bristol-Myers Squibb | Advanced Solid Tumors | 08/24 | 10/25 | | |
NCT06337604: The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets |
|
|
| Completed | 1 | 20 | RoW | TNP-2092 capsules, Rifaquizinone, TNP-2092 capsules placebo, Rabeprazole sodium enteric-coated tablets | TenNor Therapeutics Inc. | Helicobacter Pylori Infection | 11/17 | 11/17 | | |
NCT04703868: A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects |
|
|
| Completed | 1 | 88 | RoW | Rabeprazole Sodium 10mg, Reference drug, Rabeprazole Sodium 20mg | Yungjin Pharm. Co., Ltd., Seoul National University Hospital | Gastroesophageal Reflux Disease | 06/21 | 06/21 | | |
NCT05330858: Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants |
|
|
| Completed | 1 | 14 | US | ESK-001, Rabeprazole | Alumis Inc | Pharmacokinetics | 06/22 | 09/22 | | |
NCT05630677: A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects. |
|
|
| Completed | 1 | 21 | US | AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet | AstraZeneca, Parexel | Healthy Volunteers | 02/23 | 02/23 | | |
|
NCT05899829: Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant |
|
|
| Completed | 1 | 42 | Canada | Camlipixant, Rabeprazole, Rifampin | Bellus Health Inc. - a GSK company | Cough, Healthy | 08/23 | 08/23 | | |
| Recruiting | 1 | 64 | RoW | ZE46-0134 or placebo, lomonitininb, Rabeprazole, 20mg oral | Eilean Therapeutics | AML | 10/24 | 11/24 | | |
NCT05918822: A Study of Maribavir Pediatric Formulation in Healthy Adult Participants |
|
|
| Completed | 1 | 32 | US | Maribavir Commercial Tablet Formulation, TAK-620, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole | Takeda | Healthy Volunteers | 08/23 | 09/23 | | |
NCT05930119: HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study |
|
|
| Completed | 1 | 24 | RoW | HMPL-453, Rabeprazole | Hutchmed | Intrahepatic Cholangiocarcinoma | 08/23 | 08/23 | | |
ChiCTR2400084355: Bioequivalence test of palbociclib tablets in fasting state under the action of antacids |
|
|
| Completed | 1 | 36 | | In the fasting state, the subjects took rabeprazole sodium enteric-coated tablets for 7 consecutive days, and then took the palbociclib reference preparation in the first cycle, and the second cycle was the same as before, and the pibociclib test preparation was taken in the second cycle; In the fasting state, the subjects took rabeprazole sodium enteric-coated tablets for 7 consecutive days, and took the palbociclib test preparation in the first cycle, and the reference preparation of palbociclib in the second cycle | Hebei General Hospital; CSPC Ouyi Pharmaceutical Co., Ltd, CSPC Ouyi Pharmaceutical Co., Ltd. | N/A | | | | |
NCT06054464: A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants |
|
|
| Completed | 1 | 28 | US | PC14586, Rabeprazole, Famotidine | PMV Pharmaceuticals, Inc | Healthy Volunteers | 11/23 | 02/24 | | |
NCT05923411: A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults |
|
|
| Completed | 1 | 113 | US | Single dose of PF-07220060 as first Tablet Formulation, Cohort 1, first Tablet Formulation, Fasted, Single dose of PF-07220060 as second Tablet Formulation, Cohort 2, second Tablet Formulation, Fasted, Cohort 3, first Tablet Formulation, Second Dose Level, Fasted, Cohort 4, second Tablet Formulation, Second Dose level, Fasted, Single dose of PF-07220060 as a Tablet Formulation, Cohort 5, Fed, Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration, Cohort 6, Fasted PPI, Cohort 7, Fed PPI, Single dose of PF-07220060 as third tablet formulation, Cohort 8, third tablet formulation | Pfizer | Healthy Participants | 06/24 | 07/24 | | |
NCT06264440: A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants |
|
|
| Completed | 1 | 18 | US | BIIB122, DNL151, Rabeprazole | Biogen | Healthy Volunteer | 06/24 | 06/24 | | |
NCT06105983: A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults. |
|
|
| Completed | 1 | 40 | Europe | Sisunatovir, Rabeprazole 40 mg, Sisunatovir suspension, Rabeprazole 20 mg | Pfizer | Healthy | 07/24 | 07/24 | | |
NCT06417229: Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants |
|
|
| Recruiting | 1 | 82 | US | BMS-986365, CC-94676, Rabeprazole | Celgene | Healthy Participants | 01/25 | 01/25 | | |
ACTRN12624000878572: A Phase 1 Study to Evaluate the Effect of Multiple Doses of Rabeprazole on the Pharmacokinetics of a Single Dose of Radiprodil in Healthy Adult Participants |
|
|
| Completed | 1 | 18 | | | GRIN Therapeutics, Inc., GRIN Therapeutics, Inc. | Malformations of Cortical Development | | | | |
ChiCTR2400083028: A study on individualized eradication therapy of Helicobacter pylori based on detection of clarithromycin 23S rRNA resistance genotypes. |
|
|
| Not yet recruiting | 1 | 308 | | Perform clarithromycin 23S rRNA resistance gene detection using disk diffusion method for drug sensitivity cultivation. For subjects who are sensitive (without mutations) to PCR resistance gene detection, administer a quadruple therapy of clarithromycin 0.5g bid+amoxicillin 1g bid+rabeprazole 10mg bid+bismuth potassium citrate 220mg bid for 14 days; The PCR resistance gene test results showed that the subjects were resistant (mutated) to tetracycline 0.5g tid+amoxicillin 1g bid+rabeprazole 10mg bid+bismuth potassium citrate 220mg bid quadruple therapy.; Perform clarithromycin 23S rRNA resistance gene testing and disk diffusion method drug sensitivity culture testing, but both were given a combination therapy of clarithromycin 0.5g bid, amoxicillin 1g bid, rabeprazole 10mg bid, and bismuth potassium citrate 220mg bid for 14 days. | Shanghai Changhai Hospital; Shanghai Changhai Hospital, National Natural Science Foundation of China - Mechanism of KLF4-mediated dysregulation of the let family in the vesicle-derived exosome MiRNome in recurrent acute pancreatitis 82170659 2025.12.31 | Helicobacter pylori infection | | | | |
ChiCTR2300075797: Effect and mechanism of Lengzhu granule on critical disease of coronary heart disease |
|
|
| Recruiting | 1 | 74 | | According to the secondary prevention of coronary heart disease, patients were given health education, adjustment of lifestyle, control of risk factors, such as smoking cessation, control of blood pressure, blood sugar, blood lipids, etc. In terms of drug selection, single anti-platelet aggregation was given: aspirin 100mg qd or clopidogrel 75mg qd or ticagrelor 90mg bid po, lipid-stabilizing plaque: atorvastatin calcium tablet 20mg qn or rosuvastatin 10mg qn. The dosage of β-blocker was determined by the patient's blood pressure and resting heart rate, and CCB/ACEI/ARB was determined by the patient's blood pressure, blood potassium and kidney function. At the same time, gastric protection drugs were given: Iprrazole or rabeprazole enteric-coated tablets 10mg qd.; Western medicine treatment plan is the same as the control group, Chinese medicine plus Lengzhu granules (vinegar Sanling formula granules 1g, specifications: 1g granules /9g decoction pieces; Vinegar Zedoary (Guangxi Zedoary) formula granules 1g, specifications: 1g granules /8g decoction pieces; Ginger formula granule 6g, specification: 0.5g granule /6g decoction piece; Jujube formula granules 3g, specifications: 2.5g granules /3g decoction pieces; Glycyrrhiza formula granules 3g, specifications: 1g granules /3g decoction pieces; Drug production Company: Jiangyin Tianjiang Pharmaceutical Co., LTD.) Water infusion, 1 dose/day; The course of treatment is 40 days. | Guangdong Provincial Hospital of Chinese Medicine Zhuhai Hospital; Guangdong Provincial Hospital of Chinese Medicine, None | Coronary heart disease | | | | |
ChiCTR2400085260: Efficacy and safety of quadruple therapy containing tigolaxant and cefuroxime in the treatment of Helicobacter pylori infection in patients with penicillin allergy |
|
|
| Recruiting | 1 | 436 | | Tegolasen 50 mg 2/day Colloidal bismuth pectin 200 mg 2/dayCefuroxime axetil 500 mg 2/dayClarithromycin 500 mg 2/day; Rabeprazole 10 mg 2 times a day Colloidal bismuth pectin 200 mg 2/dayCefuroxime axetil 500 mg 2/dayClarithromycin 500 mg 2/day | Shenzhen Second People's Hospital; Shenzhen Second People's Hospital, Shenzhen Digestive System Disease Clinical Medicine Research Center Project | Helicobacter pylori treatment | | | | |
ChiCTR-IOR-14005512: proton pump inhibitor and H2 antagonist in the prevention of antiplatelet drugs associated upper gastrointestinal bleeding and rebleeding |
|
|
| Recruiting | N/A | 500 | | rabeprazole vs control | Department of Gastroenterology and Hepatology, the Chinese PLA General Hospital, Beijing 100853, China.; Chinese PLA General Hospital, ministry of health | upper gastrointestinal bleeding | | | | |
ChiCTR-OOC-15005857: A study about the Optimization of Helicobacter pylori resistance level, CYP2C19 polymorphism survey and eradication of Helicobacter pylori of rural population in Chongqing |
|
|
| Recruiting | N/A | 150 | | Nexium / rabeprazole + amoxicillin + furazolidone + bismuth ;Omeprazole / lansoprazole / pantoprazole + amoxicillin + furazolidone + bismuth ;Nexium / rabeprazole + amoxicillin + clarithromycin | Daping Hospital, the Third Military Medical University; Daping Hospital, the Third Military Medical University, Daping Hospital, the Third Military Medical University | diseases of upper digestive tract | | | | |
ChiCTR-IOR-15006547: A comparative study of optional dule therapy and bismuth-containing quadruple regimen for Helicobacter pylori infection |
|
|
| Not yet recruiting | N/A | 260 | | Rabeprazole 10mg qid+Amoxicillin 750mg qid 14days ;Rabeprazole 20mg tid+Amoxicillin 750mg qid 14days ;Rabeprazole 20mg qid+Amoxicillin 750mg qid 14days ;Rabeprazole 20mg bid+Bismuth 220mg bid+Amoxicillin 1000mg bid+clarithromycin 500g bid 14days | Daping Hospital, the Third Military Medical University, Chongqing, China; Daping Hospital, the Third Military Medical University, Chongqing, China, National Natrural scientific funds(81171526,81472006) | diseases of upper digestive tract | | | | |
ChiCTR-IOR-15007306: A comparative study of optional dule therapy and bismuth-containing quadruple regimen for Helicobacter pylori infection |
|
|
| Recruiting | N/A | 263 | | rabeprazole10mg qid+amoxicillin 750mg qid 14days ;rabeprazole 20mg qid+amoxicillin 750mg qid 14days ;rabeprazole 20mg bid+bismuth 220mg bid+ Amoxicillin 1g bid+clarithromycin 500mg bid 14days | Daping Hospital, the Third Military Medical University, Chongqing, China; Daping Hospital, the Third Military Medical University, Chongqing, China, National Natrural scientific funds(81171526, 81472006) | diseases of upper digestive tract | | | | |
ChiCTR-OOC-16007930: Two- years follow- up survey on H.pylori recurrence after successful eradication |
|
|
| Recruiting | N/A | 543 | | Esomeprazole 20mg bid or Rabeprazole 20mg bid + bismuth 220mg bid + Amoxicillin 1g bid + tetracycline 750mg bid + furaxone 100mg bid, 14 days | Daping Hospital, the Third Military Medical University, Chongqing, China; Daping Hospital, the Third Military Medical University, Chongqing, China, optional research topic | diseases of upper digestive tract | | | | |
ChiCTR-OQR-14004879: The role of Qing-gan-jian-pi decoction treatment of Barrett esophagus and the influence of the expression of CDX2, P38MAPK |
|
|
| Recruiting | N/A | 68 | | Qing-gan -jian-pi decoction(QGJPD) + Mosapride Cit ;Rabeprazole Sodium Enteric-coated Capsules and Mos ;Almagate Suspension and Mosapride Citrate Dispersi | XiAn Hospital of Traditional Chinese Medicine; XiAn Hospital of Traditional Chinese Medicine, No | Barrett's esophagus | | | | |
ChiCTR1800014638: The study of the treatment of Helicobacter pylori infection in children with a 10-day sequential therapy containing Rabeprazole |
|
|
| Recruiting | N/A | 690 | | 10-day sequential therapy containing Rabeprazole ;10-day sequential therapy containing Omeprazole | Guangzhou Women and Children's Medical Center; Guangzhou Women and Children's Medical Center, NA | Helicobacter pylori infection in children | | | | |
ChiCTR-IOR-16008610: Multicenter, randomized, open controlled study of standard PPI triple therapy combined with Bioflor for Hp eradication |
|
|
| Recruiting | N/A | 540 | | Bioflor+Rabeprazole+Amoxicillin+Clarithromycin (d1~d10), Bioflor (d11~d14) ;Rabeprazole+Bismuth potassium citrate+Amoxicillin+Clarithromycin (d1~d10) ;Rabeprazole+Amoxicillin+Clarithromycin (d1~d10) | Peking University First Hospital; China Health Promotion Foundation, Shenzhen Kangzhe Pharmaceutical Co.,Ltd. | Helicobacter pylori infection | | | | |
ChiCTR-INR-16009652: 'Shugan Hewei' decoction combined with Rabeprazole with the treatment of refractory gastroesophageal reflux disease: a multicenter, parallel, double-blind randomized controlled trial |
|
|
| Not yet recruiting | N/A | 240 | | TCM syndrome differentiation + PPI; Agreement prescription of traditional Chinese Medicine+PPI | Shanghai Yueyang Hospital; Shanghai Yueyang Hospital, Three year plan of action for promoting clinical skills and clinical innovation in municipal hospitals | refractory gastroesophageal reflux disease | | | | |
| Recruiting | N/A | 120 | | Rabeprazole+Clarithromycin+Amoxicillin+Bismuth Potassium Citrate ;Two Sensitive Antibiotics and Rabeprazole and Bismuth Potassium Citrate ;Two sensitive antibiotics, rabeprazole and bismuth potassium citrate plus Jinghua Weikang capsules ;Two sensitive antibiotics, rabeprazole and bismuth potassium citrate plus Lianpu Qingwei Granules | Hubei Provincial Hospital of Traditional Chinese Medicine; Hubei Provincial Hospital of Traditional Chinese Medicine, Beijing Changjiang Pharmaceutical Development Foundation | Helicobacter pylori infection | | | | |
ChiCTR2000030097: Clinical study of rabeprazole combined with mosapride in the treatment of elder patients with chronic gastritis |
|
|
| Not yet recruiting | N/A | 200 | | rabeprazole combined with mosapride ;none | Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, self raise | chronic gastritis | | | | |
ChiCTR2000037476: The bioequivalence study of single-dose, fasting and postprandial administration, two preparations, four cycles, two sequences, random, open, and repeated crossover of rabeprazole sodium enteric-coated tablets in healthy subjects |
|
|
| Not yet recruiting | N/A | 48 | | TRTR ;RTRT ;TRTR ;RTRT | The Second Affiliated Hospital of Xingtai Medical College; Rundu pharma, Rundu pharma | Gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, Zollinger-Ellison syndrome. | | | | |
ChiCTR2000031454: Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19) |
|
|
| Recruiting | N/A | 56 | | Rabeprazole plus chloroquine ;Lopinavir + rabeprazole | Infection prevention and treatment center of The Fifth Affiliated Hospital of Sun Yat-Sen University; The Fifth Affiliated Hospital of Sun Yat-Sen University, government | Novel Coronavirus Pneumonia (COVID-19) | | | | |
ChiCTR2000036656: Clinical study of Zhenzhu Qingyuan granule in the treatment of gastroesophageal reflux disease of liver-stomach heat retention type |
|
|
| Recruiting | N/A | 150 | | Zhenzhuqingyuan granule, two times oral daily. Rabeprazole Sodium Enteric-coated Tablets, each 20mg oral daily for eight weeks. ;Rabeprazole Sodium Enteric-coated Tablets, each 20mgoral daily for eight weeks. | Xiyuan Hospital CACMS; Henan Province Hospital of TCM, State Administration of Traditional Chinese Medicine | Gastrointestinal reflex disease | | | | |
ChiCTR2100049456: The bioequivalence study of rabeprazole sodium enteric-coated tablets in healthy subjects with single dose, fasting and postprandial medication, two preparations, four cycles, two sequences, random, open, and repeated crossover |
|
|
| Not yet recruiting | N/A | 112 | | fasting TRTR ;fasting RTRT ;TRTR after meal ;RTRT after meal | The Second Affiliated Hospital of Xingtai Medical College; Rundu Pharma, Rundu Pharma | Gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, Zollinger-Ellison syndrome. | | | | |
NCT03320538: Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases |
|
|
| Completed | N/A | 360 | RoW | Hou Gu Mi Xi, Placebo, Rabeprazole, Trade name: Xin Wei An | Jiangxi University of Traditional Chinese Medicine, Jiangxi Hospital of Traditional Chinese Medicine, The First Affiliated Hospital of Nanchang University, Second Affiliated Hospital of Nanchang University, The Third Affiliated Hospital of Nanchang University, Nanchang Hongdu Hospital of Traditional Chinese Medicine, Nanchang Hospital of Integrated Traditional Chinese and Western Medicine, The Nanchang Third Hospital, Xinyu People's Hospital, Xinyu Hospital of Traditional Chinese Medicine, Jiujiang No.1 People's Hospital, Jiujiang Hospital of Traditional Chinese Medicine | Peptic Ulcer Disease | 09/20 | 09/20 | | |
NCT04923113: Comparison of Different Helicobacter Pylori Detection Methods in Patients With Chronic Atrophic Gastritis |
|
|
| Completed | N/A | 281 | RoW | Histology,13C urea breath test,Stool antigen test,Serological antibody test for H.pylori and Serologic test with a current infection marker of H.pylori, Rabeprazole,Minocycline,Amoxicillin and Colloidal bismuth pectin | Second Affiliated Hospital, School of Medicine, Zhejiang University | Helicobacter Pylori Infection | 01/22 | 01/23 | | |
ChiCTR1900023200: Standardized study for Hezhong Jianpi Decoction in the drug withdrawal of cases of proton pump inhibitor-dependent gastroesophageal reflux disease |
|
|
| Not yet recruiting | N/A | 72 | | HeZhongJianPi decoction,two times oral daily, each time 100ml, ten weeks course of treatment.Rabeprazole Sodium Enteric-coated Tablets,each 20mg, two times a day orally for first four weeks, each 20mg oral daily for next two weeks,each 10mg oral daily for next two weeks. ;Rabeprazole Sodium Enteric-coated Tablets,each 20mg, two times a day orally for first four weeks, each 20mg oral daily for next two weeks,each 10mg oral daily for next two weeks. | Shanghai Municipal Hospital of Shanghai TCM University; Shanghai Municipal Hospital of Shanghai TCM University, Science and Technology Commission of Shanghai Municipality | gastroesophageal reflux disease | | | | |
ChiCTR2200057178: A prospective multicenter randomized controlled clinical study of domestic esomeprazole combined with high-dose amoxicillin in the treatment of Helicobacter pylori infection |
|
|
| Not yet recruiting | N/A | 640 | | Rabeprazole (Zhuhai Rundu Pharmaceutical Co., LTD., Rainqing) 10mg/ time, 4 times/day ;Omeprazole high-dose dual therapy | Affiliated Hospital of Southwest Medical University; Affiliated Hospital of Southwest Medical University, None | helicobacter pylori (Hp) infection | | | | |
ChiCTR2000036518: Clinical study of Shugan Hewei granule in the treatment of refractory gastroesophageal reflux disease with qi stagnation and phlegm obstruction |
|
|
| Not yet recruiting | N/A | 220 | | Traditional Chinese medicine granules ;Rabeprazole capsules | Yueyang Hospital of Integrated Traditioanl Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine; Yueyang Hospital of Integrated Traditioanl Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai Shenkang Hospital Development Center | gastroesophageal reflux disease | | | | |
ChiCTR2000037114: Clinical study on Tonghua Liyan Decoction in the treatment of gastroesophageal reflux associated pharyngitis |
|
|
| Recruiting | N/A | 190 | | Tonghua Liyan prescription ;Rabeprazole capsules | Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine; Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shenkang three-year Chinese medicine action plan subsidy | Gastroesophageal reflux disease | | | | |
ChiCTR2000036761: Clinical study on precise diagnosis and treatment of refractory gastroesophageal reflux disease by Traditional Chinese medicine based on intestinal microecological macroomics technology |
|
|
| Not yet recruiting | N/A | 210 | | Nil ;Rabeprazole capsule 20mg po QD + Mosapride tablet 5mg po TID ;TCM treatment based on syndrome differentiation 100ml po bid | Shanghai Traditional Chinese Medicine Hospital; Shanghai Traditional Chinese Medicine Hospital, Shanghai Shenkang Hospital Development Center | Gastroesophageal reflux disease | | | | |
ChiCTR2100046614: Clinical study of Tonghua Liyan recipe in the treatment of laryngopharyngeal reflux with Qi stagnation and phlegm obstruction: A randomized, double-blind, placebo-controlled trial |
|
|
| Recruiting | N/A | 82 | | Tonghua Liyan granules combined with rabeprazole capsules ;Tonghua Liyan granules placebo combined with rabeprazole capsules | Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine; Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Technology Innovation Action Plan of Shanghai Science and Technology Commission (19401971800) | Gastroesophageal reflux disease | | | | |
ChiCTR2000040469: Clinical study of different eradication regimens for Helicobacter pylori infection in adults in Yangzhou area |
|
|
| Recruiting | N/A | 150 | | Rabeprazole + amoxicillin + clarithromycin + bismuth ;Rabeprazole + amoxicillin ;Rabeprazole + 2 sensitive antibiotics | Affiliated Hospital of Yangzhou University; Affiliated Hospital of Yangzhou University, Affiliated Hospital of Yangzhou University | diseases of upper digestive tract | | | | |
ChiCTR2200065612: Clinical study on residual pain after verteboplasty for osteoporotic thoracolumbar compression fracture treated with Dingganren Decoction Mulberry cream formula |
|
|
| Not yet recruiting | N/A | 60 | | ketorolac tromethamine + Rabeprazole ;ketorolac tromethamine + Rabeprazole + Mulberry cream formula | Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine; Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Dingjiwan Foundation of Meng Heding's Internal Medicine Department, Shanghai University of Traditional Chinese Medicine | Residual pain after vertebroplasty for osteoporotic thoracolumbar compression fractures | | | | |
ChiCTR2200057113: Evaluation of Therapeutic effect of Tongjiangjieyu decoction on Gastroesophageal Reflux Disease |
|
|
| Not yet recruiting | N/A | 116 | | Tongjiangjieyu decoction ;Sodium Rabeprazole Enteric-coated Tablets | Guang'anmen Hospital, China Academy of Chinese Medical Sciences; Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Clinical research project of Wu Jieping Medical Foundation | Gastroesophageal Reflux Disease | | | | |
ChiCTR2100054125: Clinical study of Qinggan Hewei Prescription in treating refractory gastroesophageal reflux disease of liver and stomach gloomy heat type |
|
|
| Recruiting | N/A | 60 | | Qinggan Hewei Prescription Chinese medicine granule combined with rabeprazole sodium enteric-coated tablet ;Chinese medicine formula granule emulator combined with rabeprazole sodium enteric-coated tablet | Beijing Pinggu District Hospital of Traditional Chinese Medicine; Beijing Pinggu District Hospital of Traditional Chinese Medicine, Capital Health Development Scientific Research Project of Beijing Municipal Health Commission | Refractory gastroesophageal reflux disease | | | | |
ChiCTR2200059309: Vonoprazan combined with amoxicillin dual therapy for primary eradication of Helicobacter pylori infection: a prospective, multicenter, randomized controlled trial |
|
|
| Not yet recruiting | N/A | 600 | | Rabeprazole 10mg 3/day + Amoxicillin 1000mg 3/day for 14 days ;Vonolasan 20mg 2/day + Amoxicillin 1000mg 3/day for 10 days. | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Self-funded | Helicobacter pylori infection | | | | |
ChiCTR2200059248: Clinical study of Tongyang Xuanbi recipe in the treatment of chest pain Associated with gastroesophageal reflux disease with hypofunction of Yang Qi in chest:A randomized ,double-blind,placebo-controlled trial |
|
|
| Not yet recruiting | N/A | 70 | | Tongyang Xuanbi pilulas combined with rabeprazole capsules ;Tongyang Xuanbi pilulas placebo combined with rabeprazole capsules | Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine; Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Technology Innovation Action Plan of Shanghai Science and Technology Commission (19401971800) | Gastroesophageal reflux disease | | | | |
NCT06349486: Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication |
|
|
| Recruiting | N/A | 780 | RoW | vonoprazan, amoxicillin, tripotassium dicitrate bismuthate, vonoprazan, amoxicillin, rabeprazole, amoxicillin, clarithromycin | Kaohsiung Medical University | Helicobacter Pylori Eradication | 12/26 | 12/26 | | |
ChiCTR2000038409: Effect of probiotics on symptom and gut microbiota in rabeprazole treated patients with gastroesophageal reflux: A randomized, double-blind, placebo-controlled study |
|
|
| Completed | N/A | 120 | | 1-8 weeks: Rabeprazole and probiotics; 9-12 weeks: probiotics; 1-8 weeks: Rabeprazole and probiotics placebo; 9-12 weeks: probioics placebo | The First Affiliated Hospital of Nanchang University; Jiangzhong Pharmaceutical Co. LTD, Jiangzhong Pharmaceutical Co. Ltd. | gastroesophageal reflux | | | | |
ChiCTR2100047273: Clinical study on the actual effect of Qishishengjiangguiyuan granule in the treatment of gastroesophageal reflux disease based on the real world |
|
|
| Recruiting | N/A | 288 | | Qishi Shengjiang Guiyuan Granules ;Rabeprazole sodium enteric-coated capsules | The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine; The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Central government funding | Gastroesophageal reflux disease | | | | |
ChiCTR2300072681: Based on the theory of ' lung-stomach correlation ', the clinical study of Xuanfei Zhike Decoction in the treatment of reflux cough of liver-stomach heat stagnation type was discussed |
|
|
| Recruiting | N/A | 68 | | Xuanfei Zhike pilulas placebo combined with rabeprazole capsules ;Xuanfei Zhike pilulas placebo combined with rabeprazole capsules | Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine; Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai High-level Talent Leading Program for Traditional Chinese Medicine (No.ZY (2021-2023)-043) | Gastroesophageal reflux disease | | | | |